^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

Published date:
04/10/2020
Excerpt:
...anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study on the correlation between the efficacy of tirelizumab in the treatment of advanced urothelial carcinoma and intestinal flora

Excerpt:
...The investigator judges that the patient is not suitable for platinum-based drug therapy or fails first-line therapy and has high expression of PD-L1; 4. ...
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Published date:
11/06/2020
Excerpt:
...efficacy of tislelizumab 200 mg administered intravenously Q3W in patients with locally advanced or metastatic PD‐L1+ UC who progressed during or following platinum‐containing therapy….Figure 4…ORR was found to be 29.4% in patients with PD-L1 >/= 50%
DOI:
10.1111/cas.14681
Trial ID: